Long-acting injectable risperidone: An emerging tool in schizophrenia treatment

Journal of Psychosocial Nursing and Mental Health Services

Volumn 43, Issue 12, 2005, Pages 25-33

  Jarboe, Kathleen S ^a   Littrell, Kimberly ^b,c   Tugrul, Karen ^d,e  

^a Comprehensive Neurosciences Inc ^*  (United States)

^b Promedica Research Center

^c GEORGIA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e Summit Behavioral Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29744434304     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Davis, J.M., Matalon, L., Watanabe, M.D., & Blake, L. (1994). Depot antipsychotic drugs. Place in therapy. Drugs, 47, 741-773.
2. Docherty, J.P., Orogg, A.L., Kozma, C., & Lasser, R. (2002, December). Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Paper presented at the 41st annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
3. Fenton, W.S., Blyler, C.R., & Heinssen, R.K. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23, 637-651.
4. Fleischhacker, W.W., Eerdekens, M., Karcher, K., Remington, G., Llorca, P.-M., Chrzanowski, W., et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry, 64, 1250-1257.
5. Kane, J.M. (1999). Pharmacologie treatment of schizophrenia. Biological Psychiatry, 46, 1396-1408.
6. Kane, J.M. (2004). Guidelines for the use of long-acting injectable atypical antipsychotics: For whom and when a long-acting injectable atypical antipsychotic might be appropriate. Journal of Clinical Psychiatry, 65, 122-125.
7. Kane, J.M., Aguglia, E., Altamura, A.C., Ayuso Gutierrez, J.L., Brunello, N., Fleischhacker, W.W., et al. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. European Neuropsychopharmacology, 8(1), 55-66.
8. Kane, J.M., Eerdekens, M., Lindenmayer, J.P., Keith, S.J., Lesem, M., & Karcher, K. (2003). Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry, 160, 1125-1132.
9. Kemp, R., Hayward, P., Applewhaite, G., Everitt, B., & David, A. (1996). Compliance therapy in psychotic patients: Randomised controlled trial. British Medical Journal, 312, 345-349.
10. Lacro, J.P., Dunn, L.B., Dolder, C.R., Leckband, S.G., & Jeste, D.V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry, 63, 892-909.
11. Lam, Y.F., Velligan, D.I., Ereshefsky, L., Korell, S., Archuletta, D., & Miller, A. (2002, June). Intra-individual variability in plasma concentrations as an indicator of adherence in schizophrenia. Poster presented at the 42nd annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL.
12. Lasser, R.A., Bossie, C.A., Gharabawi, G.M., & Baldessarini, R.J. (2005). Clinical improvemenrs in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: A 12-month open label trial. International Journal of Neuropharmacology, 8, 427-438.
13. Lasser, R.A., Bossie, C.A., Gharabawi, G.M., & Turner, M. (2004). Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European Psychiatry, 19(4), 219-225.
14. Lasser, R.A., Ramstack, J.M., Grandolfi, G.P., Mannaert, E., & D'Hoore, P. (2003, March-April). Long-acting injectable risperidone (Risperdal® Consta™): Manufacture using Medisorb® microsphere technology, pharmacokinetics, and injection-site assessments. Poster presented at the International Congress on Schizophrenia, Colorado Springs, CO.
15. Lonchena, C., Lasser, R.A., Bossie, C., Zhu, Y., Gharabawi, G., & Baldessarini, R.J. (2003, May). Can stable patients with schizophrenia improve? The impact of partial compliance versus constant therapy. Poster presented at the annual meeting of the American Psychiatric Association, San Francisco.
16. Mahmoud, R., Engelhart, L.M., Janagap, C., Oster, G., & Ollendorf, D. (2004). Risperidone versus conventional antipyschotics for schizophrenia and schizoaffective disorder: Symptoms, health-related quality of life, and resource use under customary clinical care. Clinical Drug Investigation, 24, 275-286.
17. Marder, S.R., Conley, R., Ereshefsky, L., Kane, J.M., & Turner, M.S. (2003). Clinical guidelines: dosing and switching strategies for long-acting risperidone. Journal of Clinical Psychiatry, 64(16 Suppl.), 41-46.
18. Markowitz, J.S., Brown, C.S., & Moore, T.R. (1999). Atypical antipsychotics part I: Pharmacology, pharmacokinetics and efficacy. Annals of Pharmacotherapy, 33, 73-85.
19. Turner, M., Eerdekens, E., Jacko, M., Eerdekens, M. (2004). Long-acting injectable risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychotics. International Clinical Psychopharmacology, 19, 241-249.
20. Valenstein, M., Copeland, L.A., Blow, F.C., McCarthy, J.F., Zeber, J.E., Gillon, L., et al. (2002). Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care, 40, 630-639.
21. Walburn, J., Gray, R., Gournay, K., Quraishi, S., & David, A.S. (2001). Systematic review of patient and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry: The Journal of Mental Science, 179, 300-307.
22. Zygmunt, A., Olfson, M., Boyer, C.A., & Mechanic, D. (2002). Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry, 159, 1653-1664.